Roth Capital Partners (“ROTH”), www.roth.com, today announced that Dr. Benjamin E. Paluch and Dr. Boobalan Pachaiyappan have joined the firm’s healthcare research team, both covering the biotechnology sector. Dr. Paluch has over four years of biotechnology equity research experience across a range of therapeutic areas including oncology and immunology. Dr. Pachaiyappan’s sell-side experience spans five years, with a focus on neurology, neuropsychiatry, neuromuscular disorders and pain.
Prior to joining ROTH, Dr. Paluch specialized in biotechnology working most recently as an Associate at Robert W. Baird from 2021-2024. He began his equity research career in 2020 as a Senior Associate at Citigroup. Dr. Paluch received his Ph.D. in Molecular Pharmacology and Cancer Therapeutics from the University at Buffalo in 2016. He completed his Ph.D. research at Roswell Park Comprehensive Cancer Center in Buffalo, NY. He has published several peer-reviewed articles in high-impact journals (Clinical Cancer Research, Blood Reviews, Oncotarget and others) and was twice awarded Young Investigator Travel Awards to present his work at the Society of Hematologic Oncology annual meetings. After completing his Ph.D., he worked in a variety of roles gaining valuable experience in Research & Development, medical affairs, business development and technology transfer.
Dr. Pachaiyappan embarked on his Equity Research career as an Associate at H.C. Wainwright and quickly advanced to Vice President and Director roles. At H.C. Wainwright, he contributed significantly to 40 initiation reports, holding primary/co-primary responsibility for 20 stocks. He was awarded a Ph.D. in Medicinal Chemistry (University of Illinois at Chicago) and an M.S. in Chemistry (Virginia Tech). His scientific work has been featured in 14 peer-reviewed scientific journals and/or industry magazines, and he was a co-inventor of a World Patent. During his academic research career, he received several awards, including the Robert M. Scarborough Award for Post-Graduate Excellence in Medicinal Chemistry (American Chemical Society) and the Outstanding Young Investigator award (Alzheimer's Drug Discovery Foundation).
Jeff Martin, CFA, Co-Director of Research, commented, “I’m pleased to welcome Ben and Boobalan to our biotechnology research team. I am confident their strong scientific background and understanding of the equity markets in biotechnology will serve our clients well.”
“We are committed to expanding our research department across industries and market caps,” said Byron Roth, Executive Chairman of ROTH. “I’m confident that Ben’s and Boobalan’s expertise will provide valuable insights for our clients and help build upon our long track record in the Healthcare sector.”
Dr. Paluch commented, “I am thrilled to join ROTH and work on the Healthcare Research team. My goal is to identify promising companies that are developing new treatments for underserved diseases with asymmetric upside for investors.”
Dr. Pachaiyappan commented, “I truly appreciate the opportunity to join alongside the 218 colleagues at ROTH to add value to investors, clients and the firm. Given that SMid-cap biotech stocks are on the cusp of a breakout to the upside, I intend to take a ‘science-first’ approach to identify securities that hold therapeutic promise yet are flying under the radar and recommend them to our valued clients.”
Since 2010, ROTH has been involved in over 590 transactions for its Healthcare clients, with a total transaction value of over $25.1 Billion. (Source: ROTH 07/02/2024)
About ROTH
Roth Capital Partners, LLC ("ROTH") is a relationship-driven investment bank focused on serving growth companies and their investors. Our full-service platform provides capital raising, high impact equity research, macroeconomics, sales and trading, technical insights, derivatives strategies, M&A advisory, and corporate access. Headquartered in Newport Beach, California, ROTH is a privately-held, employee owned organization and maintains offices throughout the U.S. For more information on ROTH, please visit www.roth.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240708476348/en/
Contacts
Investor and Media Contact:
ROTH, Isabel Mattson-Pain, Managing Director and Chief Marketing Officer, imattson-pain@roth.com, 949-720-7117
